Skip to main content

Grifols shares plunged by a further 14% on Wednesday following publication of another report from short seller Gotham City Research, raising additional questions about the Barcelona medicine maker’s “transparency, integrity, and ethical conduct.” 

Grifols’ share price previously fell more than 40% in January after the short-seller Gotham posted a report on January 9 claiming the Spanish blood-plasma products maker had manipulated its balance sheets to lower its debt to earnings ratios. 


Master your money.

Subscribe to MarketWatch.

Get this article and all of MarketWatch.

Access from any device. Anywhere. Anytime.

Subscribe Now

Read the original article

Leave a Reply